Peptide encyclopedia
Every compound indexed here carries mechanism, route of administration, half-life, legal status, and the primary sources backing every claim — graded and dated.
- Compounds
- 75
- Source links
- 249
- Therapeutic classes
- 10
- Matching filter
- 9
F·Filter
Reset allMetabolic / GLP-1
GLP-1 receptor agonists and the obesity / diabetes pharmacology cluster.
9 compounds
01
Research use only
5-Amino-1MQ
5-amino-1-methylquinolinium · 5-amino-1-methylquinolinium iodide · et al.
5-Amino-1MQ is a small molecule, not a peptide — and despite vigorous biohacker interest in oral body-recomposition use, the published human evidence base is zero trials.
Half-life·Plasma half-life and oral bioavailability in humans have not…
Read entry
02
Research use only
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH(177-191) · et al.
The only peptide on this site whose pivotal trial conclusively failed — and the one most commonly stacked into compounded weight-loss protocols anyway. The page exists to reconcile that gap.
Half-life·~30 minutes plasma half-life following intravenous administr…
Read entry
03
Research use only
Apraglutide
FE 203799 · apraglutide · et al.
The once-weekly successor to teduglutide — same mechanism, longer half-life, positive Phase III primary endpoint, and an unusually instructive regulatory holdup that turns on dose preparation rather than efficacy.
Half-life·~30–50 hours plasma elimination half-life in humans after su…
Read entry
04
Research use only
Cagrilintide
AM833 · AM-833 · et al.
In REDEFINE-1 (n=3,417), CagriSema produced a 22.7% mean weight loss at 68 weeks under the trial-product estimand — below Novo Nordisk's stated 25% target, with cagrilintide-alone delivering 11.8% versus semaglutide-alone 16.1%.
Half-life·~159–195 hours (roughly 6.6–8.1 days) in healthy adults acro…
Read entry
05
Research use only
GIP
glucose-dependent insulinotropic polypeptide · gastric inhibitory peptide · et al.
Physiological GIP was the metabolic peptide that was historically considered a 'fat hormone' for its lipid-storage promotion in adipose tissue — and yet pharmacological GIP-receptor agonism inside tirzepatide produces weight loss, not weight gain. The resolution of that paradox is the editorial center of why the dual-agonist class outperforms GLP-1 monoagonism.
Half-life·~7 minutes plasma half-life for native intact GIP(1-42); rap…
Read entry
06
Research use only
GLP-1
glucagon-like peptide-1 · GLP-1 · et al.
GLP-1 is the reference molecule for the most clinically successful peptide drug class of the 21st century; its 1-to-2-minute plasma half-life is the single pharmacokinetic constraint every commercial GLP-1 receptor agonist is engineered to solve.
Half-life·~1 to 2 minutes intravenous plasma half-life in humans, with…
Read entry
07
Research use only
GLP-2
glucagon-like peptide-2 · GLP-2 · et al.
The reference molecule for the intestinotrophic peptide class — a 33-residue proglucagon fragment whose seven-minute plasma half-life is precisely the design problem teduglutide and apraglutide were engineered to solve.
Half-life·~7 minutes plasma elimination half-life in humans by intrave…
Read entry
08
Research use only
Pemvidutide
ALT-801 · pemvidutide
Pemvidutide is the third GLP-1 / glucagon dual agonist with positive Phase 2b MASH and Phase 2 obesity readouts — Altimmune's smaller-cap entrant in the same engineered-pharmacology class as Boehringer's survodutide and Lilly's mazdutide, distinguished by a balanced 1:1 receptor-engagement ratio, an unusually preserved lean-mass body-composition signature in MOMENTUM, and a Phase 3 readiness contingent on a single-sponsor financing and execution path.
Half-life·~one week; EuPort glycolipid conjugation drives near-quantit…
Read entry
09
Research use only
Survodutide
BI 456906 · NN1177
Survodutide is the GLP-1 / glucagon dual agonist whose Phase 2 obesity readout reached −14.9% mean weight loss at 46 weeks and whose Phase 2 MASH readout produced histologic MASH resolution in 62% of the 4.8-mg group versus 14% on placebo — the two trial results that anchor the most-anticipated Phase 3 program in the metabolic-hepatic pipeline outside of retatrutide.
Half-life·~132–179 hours (roughly 5.5–7.5 days) across the clinical do…
Read entry